Heading Upstream & Investing at the Source: RESI Conference Announces Big Pharma Panel

By Tom Crosby, RESI Conference Manager, LSN

Tom 2

Don’t miss an excellent chance to hear directly from pharma executives looking to fill pipeline gaps via strategic partnerships & alliances; LSN is bringing together representatives from some of the most active big pharma companies involved in early stage life sciences.

Moderated by Bill Kohlbrenner of AbbVie, the audience will hear from:

Panelists will discuss in-depth the key motivators behind big pharma’s shift towards an early stage strategy as a way to fill the gaps in their pipelines. What indication areas are the most sought after? How does an early stage entrepreneur interface with business development executives from pharmaceutical companies? LSN’s Big Pharma RESI Panelists will shed light on these questions and more.

Hear from big pharma executives as they explain how they engage with early stage startups, and how they like to be contacted. The speakers will help the audience understand their timeline for contact, and give advice on how to create a dialogue that leads to a relationship and an eventual alliance. If you need to understand the timeframe and limitations of how big pharma corporate works, this expert session is crucial for you to attend.

RESI3

 

LSN Business Development Corner: Assessing Your Fundraising Acumen

By Jack Fuller, Business Development, LSN

Jack 2

The perfect fit, the good fit, and the stretcher. Those are the three types of scientist-entrepreneurs I’ve seen do well in their fundraising efforts.

Day in and day out, LSN works with life science companies that are raising capital, and we see an enormous number of talented and intelligent people who cannot conceptualize and execute an outbound fundraising campaign. For one reason or another, otherwise smart people are not able to determine who to approach for capital or discuss their ideas and technology in a clear and convincing manner.

However, some scientist-entrepreneurs are a perfect fit or a good fit for successfully running an outbound fundraising campaign, and some can stretch and make it happen.

The Perfect Fit

This is someone who has built a team to support the fundraising process. The perfect fit realizes the importance of continually updating a contact database with the latest relevant players. He or she understands that professional marketing materials are critical. And he or she is able and willing to do whatever is necessary to secure the future of the company. With little assistance, the perfect fit can take a list of qualified investors and have meaningful dialogues that eventually lead to allocations.

The Good Fit

This usually is a person who is dedicated to fundraising. The good fit has contacts in the industry, is not afraid to pick up the phone and call a stranger, and has run a meeting with potential investors. Still, despite his or her experience, this individual often has difficulty branding the company and technology, crafting a message, and presenting not only a compelling narrative to investors but also one that’s clear so investors can determine quickly if there is a fit with their investment criteria. Because of his or her experience, however, the good fit recognizes what’s missing and can get up to speed quickly.

The Stretcher

This is often a former scientist who had a great idea, which launched a company. Then, he or she wants to get to the next level and realizes that raising money from investors is different from asking friends and family. The stretcher often needs help with fundamental sales and marketing tactics, overhauling the investor materials, and tackling list and task management. Because this individual has an uncommon desire to learn and do whatever is necessary—to stretch—he or she can become a successful fundraiser.

Which one are you?

LSN Announces Life Science Fundraising Accelerator

LSFA-LOGO-web 

FOR IMMEDIATE RELEASE

Contact:

Nono Hu, Marketing/PR Manager

(617) 580-5011

m.hu@lifesciencenation.com

LSN Announces Life Science Fundraising Accelerator

BOSTON (June 19, 2014) — Life Science Nation (LSN), in collaboration with the UMASS Boston Venture Development Center (VDC), announces Life Science Fundraising Accelerator, a program designed to fill the void in the procurement of early stage life science capital. Currently, the scientist-entrepreneur struggles to go “the last three feet” and get in front of an investor, create a dialogue, build a relationship, and secure capital allocations.

The Life Science Fundraising Accelerator is a 90-day program that:

  • Prepares start-ups for a global fundraising campaign
  • Educates the founding team on the basics of raising capital in today’s competitive landscape
  • Packages the founding team for a fundraising campaign, creating the necessary branding and messaging, including a logo, tagline, elevator pitch, executive summary, PowerPoint presentations, and investor-centric website
  • Provides tactical, hands-on, assistance in executing fundraising campaigns, including setting up a cloud-based infrastructure to manage a list of investor prospects and the required follow-up that’s associated with an outbound direct-marketing campaign

This kind of acceleration is only available today to the largest biotech and pharma companies that work with top-tier investment banks in preparation for the all-important road show before an IPO.

Initially, the ideal candidates for the Accelerator program will be emerging biotech and medtech companies that have entered (or are preparing to enter) clinical trials. These start-ups have significant animal data, and possibly even some human data, and are likely seeking $1 million to $20 million to further develop an asset through the clinical-trial process.

Dennis Ford, CEO of LSN, noted that scientist-entrepreneurs experience a conundrum when it comes funding their entity. “Everybody understands their marching orders, but hardly anyone has been given the training and tools to carry out the mission,” Ford stated.

The Accelerator has two business aspects. The first is a traditional fee for service. The second is an evergreen grant initiative. The latter program hopes to recruit incubators into the program by having them nominate scientist-entrepreneurs who are ready for a fundraising campaign. The Accelerator program will provide these scientist-entrepreneurs with an evergreen grant (details to follow). This aspect of the program intends to be a self-funding vehicle so that other entrepreneurs can have the same opportunity.

William Brah, Director of the UMASS Boston VDC, said, “LSN and the VDC have been successfully piloting a version of this program for about a year. Early discussions with the incubator community show vigorous support for the project. The Massachusetts life science community has been working closely together for years and hopefully this program will garner traction quickly.”

Life Science Nation (LSN) accelerates the business of early stage life science through a Match.com-like sourcing platform. LSN researches and curates market intelligence on global early stage investment, tracking ten categories of life science investors. LSN also manages the Redefining Early Stage Investments (RESI) conference series, which brings together global emerging biotech and medtech companies with early stage investors. LSN recently published a book, The Life Science Executives Fundraising Manifesto.

UMASS Boston’s Venture Development Center (VDC) was created to pursue new knowledge and train next-generation inventors. It is a mixed-use incubator designed to support technology and life science entrepreneurs. The VDC has a reputation for building community among life science entrepreneurs and delivering business tactics that help propel resident firms forward to commercialization.

###

Re-envisioning the Traditional Venture Model: RESI Conference Announces First Panel

By Tom Crosby, RESI Conference Manager, LSN

Tom 2There’s a lot going on in early stage venture-capital investment, and everyone is trying to follow the bouncing ball. In light of reports that venture-backed life science and biotech deals are off to their hottest start since 2007, LSN is pleased to announce the venture capital panel for the upcoming RESI ConferenceRe-envisioning the Traditional Venture Model.

The panel will have representatives from some of the biggest global VC firms. Moderated by Bernadette Adamo of Silicon Valley Bank, the audience will hear from Kush Parmar, Partner at 5AM Ventures, Jayson Punwani, Partner at Pappas Ventures, Jerel Davis, Operating Partner at Versant Ventures, and Kiran Reddy, Associate Partner at Third Rock Ventures.

Though life science VCs have faced many challenges in the past decade, this adaptive investor class has reached an inflection point of late. The delegates featured on the upcoming RESI VC panel will speak about trends they’re seeing in today’s marketplace, and their thoughts on the future of venture investments.

RESI3

 

The Medtech Fundraising Landscape for 2014

By Michael Quigley, Research Manager, LSN

mike-2There is a common perception in the industry that direct medical-device investment has all but frozen over the past few years. As a fundraising entrepreneur, this is an easy kickstand to lean on when you have trouble securing financing for your proprietary technology. Data gathered over the past nine months by the research team here at LSN paints a different, much more positive picture, however. After reaching out to thousands of investors throughout the life science industry, we have identified and interviewed more than 300 qualified investors actively seeking to allocate to the medical device space.

Many may argue that 300 investors represent the marketplace as a whole, not the investors interested in early stage, higher-risk opportunities. However, the chart below shows the highest level of investor interest lies in the venture stage, which LSN defines as companies that have raised at least one round of financing outside of friends and family but have yet to reach commercialization for their product. And while interest in the growth stage does outweigh seed, there are still a large number of investors with capital looking to invest in compelling seed-stage opportunities.

C1

Analyzing this data further, we find that the investors looking into this space are very diverse. (See the chart below)

C2

The interest in the medtech sector is also reflected in PWC’s MoneyTree Report, which shows that 25 deals accounted for total early stage medical-device funding increasing by 11% in Q1 2014 to $216 million, as compared with $194 million from 29 deals in Q1 2013. The average investment for early stage device firms also reached an all-time high of $8.6 million.

This significant uptick in dollars invested and decrease in deal volume tells us something interesting about the changing landscape: Although the numbers may not be as high as they have been historically (and it is also worth noting that PWC’s findings only include reported financings), a large group of investors are without a doubt staying involved and investing in the medical device industry. However, these investors seem to be more selective, investing more capital into slightly fewer deals. Now more than ever, it is crucial for medical device entrepreneurs to understand which investors might be interested in their specific technology and how to present the opportunity to these firms to best demonstrate value.

Source: http://www.mddionline.com/blog/devicetalk/heres-new-vc-investment-reality-of-2014-for-medtech

 

LSN Releases Book: The Life Science Executive’s Fundraising Manifesto

 FOR IMMEDIATE RELEASE

For more information

Contact: Nono Hu

Marketing/PR Manager, Life Science Nation

(617) 580-5011

m.hu@lifesciencenation.com

 

LSN Releases Book:

The Life Science Executive’s Fundraising Manifesto

BOSTON (June 12, 2014) — Dennis Ford, founder and CEO of Life Science Nation, reveals in his new book released today, The Life Science Executive’s Fundraising Manifesto, the skill sets required to seek capital in the biotech and medtech arenas.

The Life Science Executive’s Fundraising Manifesto was written to help scientists understand the fundamental skills needed to brand and market their companies. It discusses how to use a consistent message to achieve compelling results from a fundraising campaign, and it teaches life science executives how to aggregate a list of potential global investors that are a fit for their company’s products and services. The book also explains how to efficiently and effectively reach out to potential investor targets, start a dialogue that fosters a relationship, and hopefully secure capital allocations.

The Life Science Executive’s Fundraising Manifesto is now available on Amazon.com and Barnes & Noble.com. For more information about the book, please visit http://www.fundraisingmanifesto.com or contact Nono Hu, Marketing/PR Manager at (617) 580-5011.

 

About the Author

Dennis Ford, founder and CEO of Life Science Nation, is a seasoned entrepreneur who has worked extensively with global alternative investors interested in high-growth, early stage technologies. In 2012, Ford brought his expertise into the arena of life science fundraising after spotting an emerging trend: institutional investors and family offices looking to invest directly in life science companies. The need to connect investors with scientists to enable the commercialization of new drugs and medical technologies, and thereby helping to change the world, was the impetus for launching LSN.

Ford is also the author of The Peddler’s Prerogative and The Fund Manager’s Marketing Manifesto, two well-received sales and marketing books.

 

###

 

 

Anatomy of the Introductory Email

By Lucy Parkinson, Research Manager, LSN

lucy 10*10

LSN continually stresses the importance of producing quality marketing materials. Every client is advised of best practices for investor outreach. A poor presentation can hinder even the most disruptive technology from gaining traction with investors.

Recently, an investor responded to a client’s introductory email by saying it was the best he had ever received. So here we dissect that introductory email, using generic details rather than any identifying information.

Our client’s first step was to explain who he was, that he was aware of the investor’s criteria, and why he believes that his company is a good fit.

My name is John Smith, and I am the CEO of ABC Medtech, a partner of Life Science Nation (LSN). After reviewing your investment criteria and mandate with LSN, ABC seems closely aligned with [name of investor’s organization] investment priorities. After reading the brief introduction below, please review our pitch deck for detailed information.

In his first paragraph, our client began to cut through the noise and prove the relevance of his message to the investor. The client also directed the investor’s attention to the email’s attachments.

Next, our client spelled out what he was looking for: growth-stage capital for a product that’s on the market and that has specific, measurable goals for success.

ABC is seeking growth capital to accelerate the production and sales of our game-changing medical technology and to promote our mission of decreasing mortality and reducing surgical errors in [indication area].

Our client then provided a compelling two-sentence description of the product and invited the investor to click through to the company’s website to see photos and videos of the product. By providing this means of engagement, our client was able to get the investor’s interest and obtain feedback via metrics: if an investor clicked through to the website, that’s an indication of interest that’s worth our client’s follow-up time.

In the next part of the email, our client detailed how much capital he was seeking and what the company was going to do with it to further its mission.

ABC seeks to capitalize the business with up to [amount] in capital to scale production, build inventory, accelerate commercialization, and enhance marketing and sales capabilities. 

The client also went on to briefly outline the product’s major customers, the revenue it is generating, and its projected revenue for the near future. These specifics gave the investor a solid picture of ABC Medtech’s position in only a few lines of text.

Finally, our client explained ABC’s strengths as a growth-stage device company and provided a call to action that will provoke a response.

Steady growth can be sustained without capital, but the firm risks losing its window of competitive exclusivity. ABC has limited competition and significant competitive advantages, and it is poised to dominate a rapidly growing medical market.

This email is an example of how to succinctly define an opportunity to an investor. You can’t be generic; a company in a different sector with different key talking points should introduce itself in a completely different way. It’s also important to think about what will compel each investor to act; you might make a different pitch to a charitable foundation than you would to a hedge fund. But whoever you’re speaking to, conveying every necessary detail as concisely as possible is the key to ensuring that your introduction has impact.

What impression will you make on the next investor you email?